Maria L. Ascierto, Ph.D. Saint John's Cancer Institute

Saint John's Cancer Institute's Director of Translational Immunology, Maria L. Ascierto, Ph.D. Contact Dr. Ascierto via email or phone number.

Maria Libera Ascierto on LinkedIn: #aacr19

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect

View Schedule - SITC 2020

Early Career Scientist Awards - Society for Immunotherapy of Cancer (SITC)

35th Anniversary Annual Meeting & Pre-Conference Programs Your guide to SITC 2020 by SITC Communications - Issuu

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect

FINAL PROGRAM - Society for Immunotherapy of Cancer

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts, Journal of Translational Medicine

Distant antimetastatic effect of enterotropic colon cancer–derived α4β7+CD8+ T cells